ATC Group: R03DC Leukotriene receptor antagonists

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R03DC in the ATC hierarchy

Level
Code
Title
1
Respiratory system
2
Drugs for obstructive airway diseases
3
Other systemic drugs for obstructive airway diseases
4
R03DC
Leukotriene receptor antagonists

Group R03DC contents

Code
Title
Zafirlukast
Pranlukast
Montelukast
Ibudilast

Active ingredients in R03DC

Active Ingredient
Description

Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. ฮคhe CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis.

Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slowreacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.

Related product monographs

Title
Information Source
Document Type
 
FDA, National Drug Code (US)
Structured Product Labeling (SPL)
Medicines Authority (MT)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
FDA, National Drug Code (US)
Structured Product Labeling (SPL/PLR)